Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir DDI and Formulation Study
NCT02243553Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under plasma concentration-time curve at steady state up to 72 hours. Started Jan 2006; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02243553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243553.